Headache and Migraine

Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.

The program director of neurology at Zucker School of Medicine, Northwell Health, reviewed the contributions of neurologist S. Weir Mitchell, MD, and how today’s neurologists can gain insights for their own practice from Mitchell’s complicated history.

Galcanezumab, an anti-CGRP antibody, is now the first approved therapy for the treatment of episodic cluster headache just 9 months after receiving approval for the preventive treatment of migraine.

Neurology News Network for the week ending June 1, 2019.

Results of a pooled analysis of 3 clinical trials suggest that the magnitude of fingolimod’s treatment effect in MS is not affected by the presence of migraine or headache in patients.

A new tool to add to your armamentarium?

To kick off Migraine and Headache Awareness Month, the latest findings reported here may influence your approaches to diagnosis, treatment, and prevention and help you keep your patients informed.

This device, which is being prepared to launch in the US market later this year, is an alternative treatment option for acute migraine.

Around three times more women than men have migraine. This marked difference in prevalence is one of the most well-known features of the illness. Here's what history tells us.

The director of the Jefferson Headache Center at Jefferson University Hospital discussed the need for physicians to revisit how they treat patients with chronic migraine who have developed medication overuse headache.

The anti-CGRP agent was shown to decrease monthly migraine days, in addition to having higher ≥50% and ≥75% responder rates, reductions in acute medication use, and enhancements in MSQ RF-R domain scores for patients who failed ≥2 more preventives.